C
Compass Therapeutics
Discovery and development teams that work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates
About Compass Therapeutics
Compass Therapeutics is a biotechnology company focused on developing next-generation antibody therapeutics to treat cancer and autoimmune diseases. The company operates in the biopharmaceutical market, leveraging its proprietary platforms to identify and advance therapeutic leads with exceptional speed and diversity. Compass Therapeutics serves patients and healthcare providers by offering highly effective, precisely targeted therapies that bridge the innate and adaptive immune systems. The business model revolves around research and development, clinical trials, and eventual commercialization of its therapeutic candidates. Revenue is generated through partnerships, licensing agreements, and sales of approved therapies. The company is committed to innovation and collaboration, aiming to unlock the complexities of the immune system to develop groundbreaking treatments.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2014
- Headquarters
- Boston, United States
- Listing
- IPO 2021
- Employees
- 59
- Open positions
- 3
- Dealroom signal
- 89.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Dec 2025 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Aug 2025 | $120M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | −$2.2M | — | −$71M | 3214.7% |
| 2025 | $0 | -100% | −$71M | — |
| 2024 | $850K | — | −$55M | -6455.5% |
| 2023 | $0 | — | −$48M | — |
| 2022 | $0 | — | −$37M | — |
| 2021 | $0 | — | −$30M | — |
| 2020 | $0 | — | −$25M | — |
Growth signals
Latest recorded traffic for Compass Therapeutics is 11K monthly website visits, down 47.6% over the last three months. Compass Therapeutics's team grew 20.4% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
- BVBorealis Ventures
Founders Fund
Green D Ventures
The Yard Ventures
Alumni Ventures
OrbiMed
Biomatics Capital Partners
F-Prime
BioMed Ventures
Alexandria Venture Investments
Thiel Capital
Other known investors7 additional known investors
Adage Capital
Braidwell- DMDafna Capital Management
Enavate Sciences
Janus Henderson Investors
Monashee Investment Management
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Compass Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Compass Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.